

mithra

Women's Health

Mission & Vision

Mithra is a Belgian **biotech company** dedicated to transforming **Women's Health** by offering new choices through innovation, with a focus on contraception and menopause.

Our goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span.

Founders




F. Fornieri, CEO

Prof. Dr. JM Foidart

At a Glance



Worldwide Markets



Why invest?

- Breakthrough innovation with the unique hormone **Estetrol (E4)**, **a native estrogen with an improved benefit/risk profile**
- 3 late-stage potential blockbusters, including **Estelle®**, a new era in Combined Oral Contraception on the market from 2021, **Donesta®**, the next generation of Hormone Therapy and **PeriNesta®**, the first potential complete oral treatment for perimenopause
- **Strong IP Position** with over 30 patent families
- Commercial **partnerships strategy** with leaders in women's health
- **Multiple opportunities** beyond contraception and menopause
- Worldwide specialist in **long acting drug development** using polymer technology
- **Mithra CDMO**, industry partner with specialist R&D and manufacturing capabilities

Corporate strategy


To leverage the full potential of the E4 portfolio, and to develop partnering for our development and manufacturing technology platform.

Portfolio

	Product	Therapeutical area	Phase 1	Phase 2	Phase 3	Market approval
E4	Estelle®	<i>Contraception</i>				2021
	PeriNesta®	<i>Perimenopause</i>				2023
	Donesta®	<i>Menopause</i>				2023
	Under development	<i>CNS, dermatology, oncology, ect.</i>	<i>Various stages of non-clinical development of future E4-based pipeline</i>			
			Formulation	Clinical/ BioEq.	Filing	Market approval
COMPLEX THERAPEUTICS	Myring™	<i>Contraception</i>		Europe		commercialized
				U.S.		2020
	Zoreline®	<i>Oncology</i>				2022
	Tibelia®	<i>Menopause</i>				commercialized


Share Structure

as of December 31, 2019




Stock Information

as of December 31, 2019






Group Structure

Mithra Pharmaceuticals



Financials



2020 Financial calendar

- 9-Mar**
2019 Annual Results
- 22-Apr**
2019 Annual Report
- 22-May**
Annual General Meeting
- 24-Sep**
2020 Half Year Results

Analyst Coverage

- > **Berenberg**
Beatrice Allen
- > **Degroof Petercam**
Benoît Louage
- > **KBC**
Sandra Cauwenberghs
- > **Kempen**
Alexandru Cogut
- > **Kepler Cheuvreux**
Pierre-Alexandre Desir
- > **Portzamparc**
Christophe Dombu



Stay in touch!

Subscribe to our mailing list:

investors.mithra.com/en/contact/#subscribe

mithra
Women's Health

Rue Saint Georges 5 • 4000 Liège • Belgium
+32 4 349 28 22 • www.mithra.com



Further information:

Alexandra Deschner

Investor Relations

investorrelations@mithra.com

investors.mithra.com